Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
about
Strategies for modern biomarker and drug development in oncology.Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemiaDasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.Advances in haematological pharmacotherapy in 21st century.Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies.BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability.High affinity molecules disrupting GRB2 protein complexes as a therapeutic strategy for chronic myelogenous leukaemia.Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.Tyrosine kinase inhibitors as cancer therapy.Appraisal of the MTT-based assay as a useful tool for predicting drug chemosensitivity in leukemia.Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.Perhexiline maleate enhances antitumor efficacy of cisplatin in neuroblastoma by inducing over-expression of NDM29 ncRNA.Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.Philadelphia chromosome-positive acute lymphoblastic leukemia.Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning.The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents.Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer.Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.Subcapsular Liver Hematoma in Metastatic GIST Complicating Imatinib (Gleevec) Therapy.Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines.The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor.High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.Effect of imatinib on haematopoietic recovery following idarubicin exposure.Imatinib restores expression of CD62L in BCR-ABL-positive cells.Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades.Imatinib sensitizes CLL lymphocytes to chlorambucil.Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia.Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.
P2860
Q30590270-AA5B9096-0988-43E3-BDE7-81F3135A10F8Q33482818-214BC0E4-0A21-467A-9FCA-EE1E9A48F660Q33644407-CEC744FB-6FEE-482F-B80A-4ECDD5B8B859Q33843477-5422A513-E9F1-4B00-9FFB-655BCF5DBB45Q33886167-F2FDA676-8611-4073-8FDE-9876DE68457CQ34335004-C8F94AA0-3525-48AB-A309-A36D3D118DE1Q34406838-255B4BC2-7600-4F8E-8090-31260678F5A1Q34929081-4B36D78C-D41E-457C-B8D1-62E998DC5A29Q35022527-9B97E60E-30D4-4D64-A2D9-FA3395377FE3Q35104353-86040CE0-A898-464E-8078-3A51BCB9AB8CQ35128883-09B89C3A-6EC1-4B8A-A2A9-7213AC8BF363Q35166848-5EBE6E11-838E-488D-89DE-C6B29FC0D52EQ35589206-1BFA0398-D523-4B95-AB87-7F68AC42E178Q35635570-ECE9A921-B0FA-48F0-96F7-DE6EC38E2BA1Q35816396-4F06C8DB-4B78-428D-B377-29E4B299E092Q36379634-B349C203-3EB8-4146-AAA7-E2CB6BF17AB2Q36854122-EAF24AE7-53BB-4C45-8DD3-EA54589DAF31Q37109503-3E7C39E0-08B5-4954-BF68-00602CD5E310Q37613888-2F8554CA-0DCF-4CCD-9F38-63AEDEDD16D6Q38283287-81BF3E47-DF8A-4CF5-B07E-BA0A98722E4FQ38283303-E7910ECE-D4FC-4359-A461-A22F84172602Q39274492-DDA517F0-5B96-4013-9CF2-295612410B1DQ40423639-24C971DB-FBA5-46DC-9330-D50A2BE76334Q40468950-C2812DFE-7F53-4834-8F39-49A35737AE37Q40477521-84540CE8-4B5F-4FFA-9FEC-47DBF8BEF5E2Q40554269-1E056FE4-40FC-4474-9450-7798D44B35A3Q40709933-BA629521-CE18-4D6A-A851-EE4F9013D800Q41769252-220DE832-6DDF-48BC-B6CE-A05F3ED39877Q43206349-DA7D9D90-B800-40DA-8A2C-AB2BA423A3ECQ43246238-5E3A9363-FC20-47FC-AB7C-F7E3337C76D2Q44285076-388F29A6-46F9-4877-860E-55FC04218442Q44319715-44F623D0-34AA-4344-B726-16426F182069Q44417197-A45904C6-9E74-4218-B4FF-174C098D6240Q44444279-8A899DC6-29CE-450B-B5FF-30D6938C0F59Q44700424-C646602E-8E7D-4652-8901-C4732EA7916EQ44719681-DBBFE5DB-45F3-4A01-BBF8-B7CF3586C01DQ44763721-8F99713C-AD8A-4E81-8BE0-484A20798712Q44791839-ABAA440D-F2B2-4952-A964-8B16F9668F30Q45204180-932697E1-E85F-4C21-B410-39B520868092Q46426199-F8CC6591-FBC2-4A95-9876-84A4A59E522B
P2860
Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Synergistic activity of the ne ...... ic myelogenous leukemia cells.
@ast
Synergistic activity of the ne ...... ic myelogenous leukemia cells.
@en
type
label
Synergistic activity of the ne ...... ic myelogenous leukemia cells.
@ast
Synergistic activity of the ne ...... ic myelogenous leukemia cells.
@en
prefLabel
Synergistic activity of the ne ...... ic myelogenous leukemia cells.
@ast
Synergistic activity of the ne ...... ic myelogenous leukemia cells.
@en
P2093
P356
P1433
P1476
Synergistic activity of the ne ...... ic myelogenous leukemia cells.
@en
P2093
P2888
P304
P356
10.1038/SJ.LEU.2402041
P577
2001-03-01T00:00:00Z
P5875
P6179
1047159890